Patients may be very agitated during the weaning period from mechanical ventilation.
Administration of loxapine, a neuroleptic that does not notably affect ventilatory drive, may
help in obtaining an adequate level of cooperation and, therefore, in reducing the duration
of mechanical ventilation.
Randomized Double-blind Trial of Midazolam and Loxapine in Agitated Patients
University Hospital, Rouen
Neuroleptics are used since a long time in the management of severely agitated patients.
Loxapine is routinely used in our country, with, to our knowledge no severe adverse event
reported, in this indication.
However, recently, benzodiazepines have appeared interesting in agitated patients, with the
use of midazolam.
The aim of this study is to compare midazolam to loxapine in the treatment of severe agitated
patients admitted in the emergency department.
The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the
treatment of acute agitation in schizophrenic patients. The study will be conducted in 120
agitated schizophrenic patients - either newly admitted to a hospital setting or a research
unit for acute agitation or already in hospital for chronic underlying conditions. Patients
meeting entry criteria will be randomized to one of two doses of Staccato Loxapine or to
Staccato Placebo. Following administration of study drug, assessment of agitation state will
be conducted at serial time points using standard agitation scales over a 24 hour period.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.